ITK-associated lymphoproliferative syndrome is an autosomal recessive primary immunodeficiency caused by biallelic variants in the ITK gene. The alteration of this tyrosine kinase compromises T lymphocyte signaling and the response to the Epstein-Barr virus, favoring severe viral infections, lymphoproliferation, hemophagocytic lymphohistiocytosis, and an increased risk of lymphoma.
Lymphoproliferative syndrome (ITK gene)
The ITK gene encodes interleukin-2-inducible kinase, a Tec family tyrosine kinase primarily expressed in T lymphocytes and NKT cells. This protein participates in T cell receptor (TCR) signaling, regulating the activation, differentiation, and effector function of these cells. It also contributes to NKT cell maturation and immune control of viral infections, especially those related to Epstein-Barr virus (EBV).
When pathogenic variants exist in ITK, the protein partially or totally loses its function. This alters the cellular immune response and hinders EBV control, which can trigger abnormal lymphocyte proliferation, systemic inflammation, and EBV-associated lymphoproliferative diseases. The disease can manifest as severe viral infections, hemophagocytic lymphohistiocytosis, hypogammaglobulinemia, lymphoproliferative lung disease, or lymphomas. Inheritance is autosomal recessive, meaning an affected individual must inherit an altered copy of the gene from each parent. It is an ultrarare condition, described in a limited number of families, often in consanguineous settings, and without an established global founder effect.
Symptoms
The onset of ITK-associated lymphoproliferative syndrome usually occurs in infancy or adolescence, although the age of presentation is variable. The main manifestations include recurrent or persistent fever, lymphadenopathy, hepatosplenomegaly, severe or chronic EBV infections, and susceptibility to lymphomas, especially Hodgkin and non-Hodgkin lymphoma. Some patients develop hemophagocytic lymphohistiocytosis, a potentially fatal hyperinflammatory state that can present with cytopenias, liver involvement, neurological abnormalities, and multi-organ failure.
Disease management
Management requires specialized follow-up by immunology and hematology. Measures include close monitoring of EBV viral load, early treatment of infections, immunoglobulins if there is significant humoral deficiency, and specific management of lymphoproliferative or tumor complications. Hemophagocytic lymphohistiocytosis is a medical emergency and may require immunosuppression, chemotherapy according to specific protocols, and intensive support.
Hematopoietic stem cell transplantation (HSCT) is the main option with curative potential for the underlying immunodeficiency and should be considered in patients with severe disease, ideally before irreversible organ damage.
Genes analyzed
Bibliography
Wallace JG, Alosaimi MF, Khayat CD, et al. ITK deficiency presenting as autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2021 Feb;147(2):743-745.e1.
López-Nevado M, González-Granado LI, Ruiz-García R, et al. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. Front Immunol. 2021 Aug 10;12:671755.
